

## CV of Bhriku Kumar Das

Name: Dr. Bhriku Kumar Das

Designation: Assistant Professor

Address for Communication: (office) Assistant Professor, Department of Pharmacology,  
Girijananda Chowdhury Institute of Pharmaceutical  
Science (GIPS), NH37, Azara, Guwahati-781017,  
Assam, India.

Mobile No.: +91-8011831765

WA No: +91-8011831765

Email: bhrigu@gips-guwahati.ac.in

Sex: Male

Date of Birth: 31-08-1990

### Educational Qualifications:

| Sl. No. | Examination Passed                         | Year of passing | Board / Council / University                                     | Specialization                          |
|---------|--|-----------------|--|---|
| 1       | HSLC/10 <sup>th</sup> Std.                 | 2006            | SEBA, Guwahati   | --                                      |
| 2       | HSSLC/10+2 Std.                            | 2008            | AHSEC, Guwahati  | --                                      |
| 3       | Degree (B. Pharm)                          | 2013            | Gauhati University   | Pharmacy                                |
| 4       | Master's Degree (M. Pharm in Pharmacology) | 2015            | KLE University, Karnataka  | Pharmacology                            |
| 5       | M. Phil.(Please Specify)                   |                 |  |   |
| 6       | Ph. D. (Pharmaceutical Science)            | 2022            | KLE University, Karnataka  | Pharmaceutical Science                  |
| 7       | Post-Doctoral (Please Specify)             |                 |  |   |
| 8       | Others (PGDCR&PV)                          | 2015            | ICBio, CRO, Innovative Centre for Biosciences, Bangalore, India. | Clinical Research and Pharmacovigilance |

Languages known: (Read, Write & Speak)

English, Assamese, Hindi.

Academic/ Administrative Experience:

1. Teaching experience (3.5 years).
2. Research experience (6.0 years).

List of Publications:

Research/Review articles:

1. **Das, B.K.**, 2022. Altered gut microbiota in hepatocellular carcinoma: Insights into the pathogenic mechanism and preclinical to clinical findings. *APMIS*. [**Impact Factor: 3.428**]
2. **Das, B.K.**, K, Jayalakshmi, Gadad P.C., 2022. <sup>1</sup>H-NMR-based serum metabolomic study to evaluate the effect of asarone and metformin on experimentally induced diabetic hepatocellular carcinoma in rats. *Bull. National Res Centre*. 46:164.
3. **Das, B.K.**, Gadad P.C., 2021. Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects. *Diabetes Epidemiol Manag*. 4:100025.
4. **Das, B.K.**, Saha, D, Gadad, P.C., 2021. *In silico* discovery of novel phytoconstituents of *Diplazium esculentum* Retz. against diabetes mellitus. *Chemistry Africa*. 4:1-12.
5. **Das, B.K.**, Knott, R.M., Gadad, P.C., 2021. Metformin and asarone inhibit HepG2 cell proliferation in a high glucose environment by regulating AMPK and Akt signaling pathway. *Futur. J. Pharm. Sci.*, 7: 43.
6. **Das, B.K.**, Gadad, P.C., 2020. Asarone and metformin modulates the oxidant-antioxidant imbalance on experimentally induced hepatocellular carcinoma during diabetic condition. *Indian J. Pharm. Educ. Res.*, 54:1039-1045. [**Impact Factor: 0.843**]
7. **Das, B.K.**, Choukimath S.M., Gadad, P.C., 2019. Asarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu. *Life Sci.*, 230:10-8. [**Impact Factor: 6.78**]
8. **Das, B.K.**, Swamy, A.H.M.V., Koti, B.C., Gadad, P.C., 2019. Experimental evidence for use of *Acorus calamus* (asarone) for cancer chemoprevention. *Heliyon*. 5: e01585. [**Impact Factor: 3.77**]

9. Krishna, R.J., Pandagale, A., Ronad, P.M., Honnalli, S.S., **Das, B.K.**, Gadad, P.C., 2019. Synthesis and pharmacological evaluation of schiff bases of 7-amino-4-methyl coumarins as novel anti-inflammatory agents. *Asian J. Pharm. Pharmacol.*, 5: 693-700.
10. **Das, B.K.**, Koti, B.C., Patil, S.B., Gadad, P.C., 2019. Effect of *Lycopersicon esculentum* (tomato) on membrane-bound ATPases against diethylnitrosamine (DEN) induced and phenobarbital (PB) promoted hepatocellular carcinoma (HCC) in rats. *Asian J. Pharm. Pharmacol.*, 5: 565-571.
11. Singh, M.K., **Das, B.K.**, Choudhary, S., Gupta, D., Patil, U.K., 2018. Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. *Biomed. Pharmacother.*, 106: 991-1002. [**Impact Factor: 7.41**]
12. **Das, B.K.**, Koti, B.C., Gadad, P.C., 2016. Role of *Lycopersicon esculentum* in diethylnitrosamine-induced and phenobarbital-promoted hepatocellular carcinoma. *Indian J. Health Sci.*, 9:147-52.
13. **Das, B.K.**, Kulkarni, J.M., 2016. The landscape of therapeutic cancer vaccine. *Int. J. Pharm. Sci. Res.*, 7:514-519.
14. **Das, B.K.**, Singh, M.K., Kulkarni, J.M., 2016. Potential gastroprotective medicinal plants: An overview. *Int. Res. J. Pharm.*, 7: 8-14.
15. Singh, M.K., **Das, B.K.**, Patidar, P., 2016. The effect of methanolic extract of *Buchanania lanzan* Spreng seeds on hematological indices. *Indian J. Pharmacol.*, 48: 214-215. [**Impact Factor: 2.83**]
16. Singh, M.K., **Das, B.K.**, Trivedi, R., 2016. *In vivo* evaluation of immunomodulatory potential of ferulic acid. *Int. Res. J. Pharm.*, 7: 12-17.
17. **Das, B.K.**, 2015. A brief scenario of Dengue virus. *Int. J. Curr. Res.*, 7: 12864-12873.
18. **Das, B.K.**, 2014. An overview on Hirudotherapy/leech therapy. *Indian Res. J. Pharm. Sci.*, 1:33-45.

Conference publications:

1. Kiba, A, Saha, D., **Das, B.K.**, NMPB (Ministry of AYUSH) Govt. of India Sponsored National Conference. Nagaon, Assam, India. Page no: 93, Jan, 2022.
2. Kamaiah, J., **Das, B.K.**, Gadad P.C., 24<sup>th</sup> Conference of National Magnetic Resonance Society. Department of Physics, IISER Mohali, Punjab, India. Page no: 66, Feb, 2018.

3. **Das, B.K.**, Koti, B.C., Swamy, A.H.M.V., Gadad P.C., World Congress on Drug Discovery Development. J N Tata Auditorium, Indian Institute of Science, Bengaluru. Page no: 1, Nov, 2016.

Research Experience:

- Doctoral thesis guided: NIL.
- Research & Consultancy Projects:
  1. Received a grant of ₹ 1.10 Crore from the Department of Science and Technology-Fund for Improvement of S&T Infrastructure (DST-FIST) [SR/FST/COLLEGE-/2021/1172 (as a part of the Project Implementation Group (PIG)]-2022.


Membership of Professional bodies:

1. Lifetime membership of the Human Ethics Committees Association (HECA), Bangalore, Karnataka, India.

Award, Fellowship & Recognition:

1. Full-time Ph.D. Research Scholar grant (of contingency and scholarship) from KLE University, Belgaum, Karnataka (2016-2019).
2. Received a fellowship from the AICTE, Government of India (August 2013 to July 2015) for qualifying for the Graduate Pharmacy Aptitude Test (GPAT) conducted by All India Council for Technical Education (AICTE)-2013.

Date: 09.01.23



Scanned Signature  
(Bhriku Kumar Das)